Table 1. Patients with myocarditis.

Patient	Age	Sex	IHCa	PVB19	PMN	NETs	Medication	Symptoms	LVEF at diagnosis (%)	Follow up (yr)	LVEF at follow up
1	47	f	+	+	+	−	BB, ACEI, diuretics	Heart failure	10	3	32%
2	29	f	+	+	+	−	BB, ACEI, MRA, diuretics	Heart failure	28	11	41%
3	48	m	+	+	+	−	BB, ACEI, MRA, diuretics	Heart failure	29	None	—
4	36	m	+	+	+	−	BB, ACEI, corticosteroids	Cardiac arrest	30	<1	Normalized
5	44	m	+	+	+	+	BB, ACEI, diuretics	Heart failure and angina pectoris	37	None	—
6	30	f	+	+	+	+	BB, ACEI, diuretics	Heart failure	45	10	Normalized
7	24	f	+	−	+	+	ACEI	LV thrombus	Normal	None	—
8	55	m	+	−	+	+	BB, ACEI	Heart failure	30	10	Normalized
9	75	f	+	−	+	+	BB, MRA, diuretics	Angina pectoris	30	None	—
10	46	m	+	−	+	+	BB, ACEI, MRA, diuretics	Heart failure	27	<1	40%
11	64	m	+	−	+	+	BB, ACEI, diuretics	Heart failure	25	<1	27%
12	56	m	+	−	+	+	BB, ACEI, MRA, diuretics	Heart failure	18	<1	45%
13	Unknown	m	+	−	+	+	Unknown	Unknown	Unknown	Unknown	Unknown
14	37	m	+	−	+	+	BB, ACEI, MRA, diuretics	Heart failure	23	None	—

ACEI, angiotensin-converting enzyme inhibitor; BB, beta blocker; f, female; LV, left ventricle; LVEF, left ventricular ejection fraction; m, male; MRA, mineralocorticoid receptor antagonist.

^a≥ 14 leukocytes/mm² and HLA-DR overexpression.